Rhythm Pharmaceuticals
RYTM
167 hedge funds and large institutions have $2.95B invested in Rhythm Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 26 closing their positions.
281% more call options, than puts
Call options by funds: $42.6M | Put options by funds: $11.2M
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
0.12% less ownership
Funds ownership: 113.24% → 113.12% (-0.12%)
1% less funds holding
Funds holding: 168 → 167 (-1)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
4% less capital invested
Capital invested by funds: $3.08B → $2.95B (-$130M)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$48.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$35.4M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$25.3M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$13.6M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$28.4M |
| 2 |
VA
VR Adviser
New York
|
-$22.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.9M |
| 4 |
CC
Commodore Capital
New York
|
-$21.9M |
| 5 |
Primecap Management
Pasadena,
California
|
-$13.4M |
RYTM Hedge Fund Activity: Q1 2024 in Review
167 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2024, worth a combined $2.95B — down 4.2% from $3.08B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RYTM and 25 opened new positions — a net loss of 1 holder — while 54 trimmed existing stakes and 63 added.
The largest buyer was Perceptive Advisors, adding an estimated $48.8M. The largest seller was Federated Hermes, cutting an estimated $28.4M.
- 167 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2024, down from 168 in Q4 2023.
- Funds reported $2.95B of Rhythm Pharmaceuticals stock for Q1 2024, down 4.2% quarter-over-quarter.
- 25 funds opened new Rhythm Pharmaceuticals positions in Q1 2024 and 26 closed out, a net change of -1 holder.
- The largest Rhythm Pharmaceuticals buyer in Q1 2024 was Perceptive Advisors, an estimated $48.8M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2024 was Federated Hermes, an estimated $28.4M sold.
Based on aggregated 13F filings for Q1 2024.